OTC · EIGRQ
Eiger BioPharmaceuticals, Inc.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
Loading market information…
NASDAQ · PLXP · USD
Stock price, earnings
Quote as of Apr 12, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PLx Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PLx Pharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PLx Pharma Inc. is a U.S.-based entity leveraging its innovative drug delivery platform technology, having successfully transitioned into the commercial stage. The company's primary offerings include Vazalore 325 mg, which is formulated for individuals facing vascular incidents like heart attacks and clot-induced strokes, as well as for the management of pain and inflammation. Additionally, they provide Vazalore 81 mg in the form of liquid-filled aspirin capsules. Looking ahead, their product development pipeline features PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, both of which are in Phase I clinical trials for addressing pain, inflammation, and fever. PLx Pharma makes its products available to consumers through a variety of retail avenues, including pharmacies, major retailers, supermarkets, and online sales channels. Founded in 2002, PLx Pharma Inc. is headquartered in Sparta, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 6, 2021 |
| -$0.37-60.87% vs estimate |
| $0.00 |
| Q1 2021 | May 14, 2021 | -$0.25-47.06% vs estimate | $0.00 |
|---|
KEEP COMPARING
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$1.75+$0.03 (+1.74%)
Vyome Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.32% below the high.
$4.93-$0.17 (-3.33%)
Palatin Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.1% below the high.
$5.62+$1.35 (+31.62%)
Applied DNA Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.24% below the high.
$0.09-$0.03 (-24.84%)
Novan, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.17% below the high.
$6.60-$0.16 (-2.38%)
SeqLL Inc.: Healthcare · Medical - Diagnostics & Research.
$0.08-$0.02 (-15.9%)
Aspira Women's Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.74% below the high.
$0.25-$0.09 (-27.68%)
Notable Labs, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
